HONG KONG, SHANGHAI & FLORHAM PARK, N.J., April 29, 2026
HUTCHMED (China) Limited has announced that the New Drug Application (NDA) for sovleplenib, a novel oral Syk inhibitor, has been accepted for review and granted Priority Review by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with warm antibody autoimmune hemolytic anemia (wAIHA) who have shown insufficient response to at least one prior glucocorticoid treatment. The therapy has also received Breakthrough Therapy Designation, highlighting its potential to address a serious condition with limited effective treatment options.
Strong Clinical Data Supports Regulatory Progress
The NDA submission is supported by positive results from the ESLIM-02 Phase II/III clinical study, a randomized, double-blind, placebo-controlled trial conducted in China involving adult patients with primary or secondary wAIHA who had relapsed or were refractory after at least one prior standard treatment. In January 2026, the Phase III portion successfully met its primary endpoint, demonstrating a durable hemoglobin (Hb) response rate between weeks 5 and 24 of treatment.
Earlier Phase II results, published in The Lancet Haematology in January 2025, showed strong clinical benefit with an overall response rate of 43.8% versus 0% for placebo in the first 8 weeks, and an expanded 66.7% overall response during 24 weeks of sovleplenib treatment, including crossover patients. The study also demonstrated a favorable safety profile, strengthening confidence in its long-term treatment potential.
Addressing a High-Unmet Need in Rare Hematology
Advertisement
Autoimmune hemolytic anemia (AIHA) is a serious autoimmune disorder where the immune system destroys red blood cells, leading to anemia, fatigue, and potentially life-threatening complications. wAIHA is the most common form, accounting for approximately 75–80% of adult AIHA cases, yet treatment options remain limited, particularly for patients who fail steroid therapy.
Sovleplenib works by targeting spleen tyrosine kinase (Syk), a critical signaling molecule involved in B-cell receptor and Fc receptor pathways. By inhibiting Syk, the therapy aims to reduce both the destruction of antibody-coated red blood cells and the production of disease-causing antibodies. This mechanism offers a targeted oral alternative to conventional immunosuppressive therapies.
Expanding Hematology Pipeline Beyond wAIHA
The wAIHA NDA marks the second NDA submission for sovleplenib, following its development in immune thrombocytopenia (ITP). HUTCHMED previously reported positive Phase III results from the ESLIM-01 trial in ITP, and the resubmitted NDA for ITP was accepted with Priority Review in February 2026. With approximately 430,000 existing ITP patients in China and many failing current therapies, sovleplenib could become a major new hematology asset for the company.
HUTCHMED retains full global rights to sovleplenib and continues to strengthen its position in both oncology and immunological diseases through internally developed targeted therapies. With Priority Review, Breakthrough designation, and strong clinical validation, sovleplenib is emerging as a promising new treatment option for patients with difficult-to-manage autoimmune blood disorders.
Source: HUTCHMED press release
